CA2468342A1 - Use of polycyclic phenolic compounds for the treatment of opthalmic diseases - Google Patents

Use of polycyclic phenolic compounds for the treatment of opthalmic diseases Download PDF

Info

Publication number
CA2468342A1
CA2468342A1 CA002468342A CA2468342A CA2468342A1 CA 2468342 A1 CA2468342 A1 CA 2468342A1 CA 002468342 A CA002468342 A CA 002468342A CA 2468342 A CA2468342 A CA 2468342A CA 2468342 A1 CA2468342 A1 CA 2468342A1
Authority
CA
Canada
Prior art keywords
cell death
cells
pharmaceutical composition
accordance
effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002468342A
Other languages
English (en)
French (fr)
Inventor
James Alan Dykens
Katherine Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2468342A1 publication Critical patent/CA2468342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002468342A 2001-12-05 2002-12-05 Use of polycyclic phenolic compounds for the treatment of opthalmic diseases Abandoned CA2468342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33659901P 2001-12-05 2001-12-05
US60/336,599 2001-12-05
PCT/US2002/039098 WO2003047559A1 (en) 2001-12-05 2002-12-05 Use of polycyclic phenolic compounds for the treatment of opthalmic diseases

Publications (1)

Publication Number Publication Date
CA2468342A1 true CA2468342A1 (en) 2003-06-12

Family

ID=23316822

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002468342A Abandoned CA2468342A1 (en) 2001-12-05 2002-12-05 Use of polycyclic phenolic compounds for the treatment of opthalmic diseases

Country Status (6)

Country Link
US (1) US20030105167A1 (https=)
EP (1) EP1463494A1 (https=)
JP (1) JP2005515992A (https=)
AU (1) AU2002359635A1 (https=)
CA (1) CA2468342A1 (https=)
WO (1) WO2003047559A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213310A1 (en) * 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
US7300926B2 (en) * 2002-04-01 2007-11-27 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for estrogen replacement therapy
US7186707B2 (en) * 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
ES2279946T3 (es) * 2002-04-01 2007-09-01 University Of Florida Research Foundation, Inc. Quinoles esteroideos como profarmacos de antioxidantes.
US7578996B2 (en) * 2004-04-07 2009-08-25 Advanced Medical Optics, Inc. Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions
US6973795B1 (en) * 2004-05-27 2005-12-13 American Standard International Inc. HVAC desiccant wheel system and method
US20060188492A1 (en) * 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6350739B1 (en) * 1999-08-11 2002-02-26 University Of Florida Resarch Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6197833B1 (en) * 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
US5877169A (en) * 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US6319914B1 (en) * 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
DE19654750A1 (de) * 1996-12-30 1998-07-02 Helmut Dr Med Zander Verwendung von Wirkstoffen mit Östrogen-Wirkung zur Vorbeugung und Behandlung von Makuladegeneration
EP0977578B1 (en) * 1997-01-16 2004-03-31 University Of Florida Research Foundation, Inc. Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
EP1032397A1 (en) * 1997-11-24 2000-09-06 University Of Florida Research Foundation, Inc. Testosterone inhibitors and use for the protection of neurons
CA2321560C (en) * 1998-03-13 2007-05-22 Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
US6326365B1 (en) * 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US6339078B1 (en) * 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
ES2287184T3 (es) * 2000-11-03 2007-12-16 Washington University Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora.

Also Published As

Publication number Publication date
JP2005515992A (ja) 2005-06-02
AU2002359635A1 (en) 2003-06-17
US20030105167A1 (en) 2003-06-05
EP1463494A1 (en) 2004-10-06
WO2003047559A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
Osborne et al. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent
Cheung et al. Neuroprotection in glaucoma: drug-based approaches
Roof et al. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone
ES2386786T3 (es) Método para tratar rubor cutáneo usando agonistas selectivos de receptores alpha-2-adrenérgicos.
Yokota et al. Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion
Tomas-Camardiel et al. Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17β-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum
Nakamagoe et al. Estradiol protects the cochlea against gentamicin ototoxicity through inhibition of the JNK pathway
Yang et al. Potential of CeCl3@ mSiO2 nanoparticles in alleviating diabetic cataract development and progression
WO2022229932A1 (en) Hypoxia inducible factor (hif) inhibitors for treatment of atrophy associated with retinal hypoxia
KR20010075621A (ko) 에스트로겐의 에난티오머를 사용한 허혈성 손상으로부터의세포 보호 방법
CN107106627A (zh) 抗氧化眼药水
US20030105167A1 (en) Treatment of opthalmic diseases
Herbort et al. Diclofenac drops to treat inflammation after cataract surgery
Lagrèze et al. The neuroprotective properties of gabapentin-lactam
Shirai et al. Deferiprone protects against photoreceptor degeneration induced by tunicamycin in the rat retina
Li et al. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous
JP2005515992A5 (https=)
Zand et al. Ocular safety of intravitreal ethylene diamine tetra acetic acid (EDTA): An experimental feasibility study
US20180085329A1 (en) Methods for treating ocular diseases
Cooley-Themm et al. Loss of displaced starburst amacrine cells in a rat glaucoma model
EA029157B1 (ru) Терапия макулярной дегенерации на основе баклофена и акампросата
US20030050295A1 (en) Use of non-feminizing estrogens as treatment for retinal vascular diseases
US20240058308A1 (en) Treatment and prevention of dry macular degeneration
CN107530319B (zh) 用于治疗眼疾的化合物
US20240108608A1 (en) Methods and compositions for the treatment of corneal endothelium disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued